Horizon Pharma (HZNP) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Nasdaq, S&P 500 slip from record highs as yields and oil rebound
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Horizon Pharma Plc (HZNP) Should Benefit From M&A - Mizuho
May 10, 2016 6:37 AM EDTMizuho analyst, Irina Koffler, trimmed her PT on Horizon Pharma (NASDAQ: HZNP) to $24 from $25 while maintaining her Buy rating. Despite seeing a challenging 2016, she thinks the company should benefit from M&A making the risk/reward is still attractive.
HZNP reported 1Q:16... More



